Newsletter Subject

Top Ways to Trade a Potential $100 Billion Obesity Treatment Boom

From

behindthemarkets.com

Email Address

newsletter@lg.behindthemarkets.com

Sent On

Tue, Apr 2, 2024 01:01 PM

Email Preheader Text

One company is about to start phase 2 trials One company is about to start phase 2 trials ?

One company is about to start phase 2 trials One company is about to start phase 2 trials                                                                                                      [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here.  Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor, Biotech is one of the hottest sectors on the market. In fact, a big part of the reason why is obesity. Since the start of the year, Eli Lilly (LLY) jumped from about $560 to $778. Part of that was thanks to sales of its obesity drug, Zepbound which saw $175.8 million in its first month out. Even better, Eli Lilly is seeing positive results in Phase 2 drug trials for patients with NASH, or nonalcoholic steatohepatitis, which impacts about 115 million patients all around the world. Or, look at Novo Nordisk (NVO), which jumped from about $95 to a high of $135 thanks to Wegovy obesity drug sales, too. The company even forecast another year of double-digit sales growth for this year, and expects to boost U.S. supplies of Wegovy again this year. --------------------------------------------------------------- [Wall Street Stockpicker Names #1 AI Stock of 2024]( The greatest quantitative mind on Wall Street just revealed his #1 A.I. pick, 100% free. [Click here to learn more...]( --------------------------------------------------------------- There’s also Viking Therapeutics (VKTX). The company is seeing good success with its GLP-1 obesity drug trials. It already reported that its Phase 2 VENTURE trial successfully achieved is primary endpoint and all secondary endpoints. It also said patients receiving VK-2735 demonstrated weight loss after 13 weeks, rating up to 14.7% from baseline weight. It's also about to start Phase 2 trials of its once-a-day weight loss pill. Viking said patients who received the pill once a day lost up to 5.3% of their weight on average, or up to 3.3% more than those who took a placebo, at 28 days, as noted by CNBC. This is just the start, though. --------------------------------------------------------------- [The 10-Minute Trader [Just One Easy Trade]]( Hugh Grossman introduces a unique "day trading" system that involves just one simple option trade taking 10 minutes a day, unlike traditional day trading involving hours glued to the screen. This fast and easy system requires opening an email, typing in the option symbol, setting the profit target, and walking away for the rest of the day. Only 87 new option traders today get to see how this new way to trade works, so better hurry. [Click here for the 10-minute simple options trading day.]( --------------------------------------------------------------- We also have to consider the obesity drug market could explode to $100 billion by 2030, says Goldman Sachs. “The obesity market is still in its early stages,” Chris Shibutani, senior biopharmaceuticals analyst in Goldman Sachs Research, writes in the team’s report, noting there are uncertainties around the assumptions in the team’s model. The $100 billion forecast is “relatively sensitive to minor tweaks to underlying drivers.” In addition, according to the World Health Organization, obesity has tripled since 1975. More than 1.9 billion adults were overweight as of 2016, with more than 650 million considered obese. Plus, more than 340 million children were considered overweight in 2016, as well.  At the rate we’re going, obesity will be the downfall for millions. However, if millions of people can take a pill or get a shot to help lose weight, it could create an unbelievable multi, multi-billion-dollar opportunity. --------------------------------------------------------------- [Potential Danger For Retirement Accounts Tied to Stocks]( Market Corrections can eat into the value of your account. This FREE Guide can help you discover ways that may assist in keeping more of your money where you want it. [GET YOUR FREE GOLD GUIDE NOW]( --------------------------------------------------------------- [Join Daily Guru Trades!]( Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.]( Are you invested in weight loss stocks? Do you have your eye on any we might have missed? Hit "reply" to this email and let us know! "The Buck Stops Here" Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Behind the Markets](  [Unsubscribe]( Â

Marketing emails from behindthemarkets.com

View More
Sent On

08/06/2024

Sent On

08/06/2024

Sent On

08/06/2024

Sent On

07/06/2024

Sent On

07/06/2024

Sent On

07/06/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.